参考文献/References:
[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[2]Duma N,Santana-Davila R,Molina JR.Non-Small Cell Lung Cancer: Epidemiology,Screening, Diagnosis,and Treatment[J].Mayo Clin Proc,2019,94(8):1623-1640.[3]Jonna S,Subramaniam DS.Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update[J].Discovery Medicine,2019,27(148):167-170.[4]Paz-Ares L,Socinski MA,Shahidi J,et al.Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase Ⅲ study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer[J].Annals of Oncology,2016,27(8):1573-1579.[5]Alexander M,Kim SY,Cheng H.Update 2020: Management of Non-Small Cell Lung Cancer[J].Lung,2020,198(6):897-907.[6]Kohno N,Inoue Y,Hamada H,et al.Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9[J].Int J Cancer Suppl,1994,8:81-83.[7]Stahel RA,Gilks WR,Lehmann HP,et al.Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis[J].Int J Cancer Suppl,1994,8:6-26.[8]Tomita M,Ayabe T,Chosa E,et al.Prognostic Significance of a Tumor Marker Index Based on Preoperative Serum Carcinoembryonic Antigen and Krebs von den Lungen-6 Levels in Non-Small Cell Lung Cancer[J].Asian Pac J Cancer Prev,2017,18(1):287-291.[9]Zheng M,Lou A,Zhang H,et al.Serum KL-6, CA19-9, CA125 and CEA are Diagnostic Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Chinese Population[J].Rheumatology and Therapy,2021,8(1):517-527.[10]Tomita M,Ayabe T,Chosa E,et al.Prognostic significance of preoperative serum Krebs von den Lungen-6 level in non-small cell lung cancer[J].General Thoracic and Cardiovascular surgery,2016,64(11):657-661.[11]Zhao J,Han Y,Li J,et al.Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer[J]. Oncology Letters,2019,17(3):3233-3240.[12]Schabath MB,Cote ML.Cancer Progress and Priorities: Lung Cancer[J].Cancer Epidemiology,Biomarkers & Prevention,2019,28(10):1563-1579.[13]Hirsch FR,Suda K,Wiens J,et al.New and emerging targeted treatments in advanced non-small-cell lung cancer[J].Lancet (London, England),2016,388(10048):1012-1024.[14]Arbour KC,Riely GJ.Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review[J].JAMA,2019,322(8):764-774.[15]Ramalingam SS,Owonikoko TK,Khuri FR.Lung cancer: New biological insights and recent therapeutic advances[J].CA: A Cancer Journal for Clinicians,2011,61(2):91-112.[16]Pao W,Girard N.New driver mutations in non-small-cell lung cancer[J].The Lancet Oncology,2011,12(2):175-180.[17]Korpanty GJ,Graham DM,Vincent MD,et al.Biomarkers That Currently Affect Clinical Practice in Lung Cancer:EGFR, ALK, MET, ROS-1, and KRAS[J].Frontiers in Oncology,2014,4:204.[18]Hirasawa Y,Kohno N,Yokoyama A,et al.KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts[J].American Journal of Respiratory Cell and Molecular Biology,1997,17(4):501-507.[19]Hirasawa Y,Kohno N,Yokoyama A,et al.Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer[J].American Journal of Respiratory and Critical Care Medicine,2000,161(2 Pt 1):589-594.[20]Farahmand L,Merikhian P,Jalili N,et al.Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents[J].Current Cancer Drug Targets,2018,18(8):737-748.[21]Sato S,Kato T,Abe K,et al.Pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression[J].Oncology Letters,2017,14(1):776-786.[22]Namba M,Hattori N,Hamada H,et al.Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1[J].Cancer Letters,2019,442:31-39.[23]Kubo N,Araki K,Yamanaka T,et al.Perioperative management of hepatectomy in patients with interstitial pneumonia:a report of three cases and a literature review[J].Surgery Today,2017,47(10):1173-1179.[24]Horimasu Y,Ishikawa N,Tanaka S, et al.MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study[J].BMC Cancer,2017,17(1):263.[25]Kumar S,Sharawat SK,Ali A,et al.Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients[J].Current Problems in Cancer,2020,44(4):100540.[26]Shoji F,Yamazaki K,Kouso H,et al.Predictive Impact for Postoperative Recurrence of Preoperative Serum Krebs von den Lungen-6 Concentration in Pathologic Stage IA Non-Small Cell Lung Cancer[J].The Annals of Thoracic Surgery,2016,101(5):1903-1908.[27]Tanaka S,Hattori N,Ishikawa N,et al.Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer[J].International Journal of Cancer,2012,130(2):377-387.[28]Ogawa Y,Ishikawa T,Ikeda K,et al.Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer[J].Clinical Cancer Research,2000,6(10):4069-4072.[29]Xu H,Inagaki Y,Tang W,et al.Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma[J].Hepato-gastroenterology,2008,55(88):2000-2004.[30]Kimura T,Tanaka S,Haruma K,et al.Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer[J].International Journal of Oncology,2000,16(1):55-64.[31]Kurosaki M,Izumi N,Onuki Y,et al.Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients[J].Hepatology Research,2005,33(3):250-257.[32]Yamasaki H,Ikeda S,Okajima M,et al.Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors[J].International Journal of Oncology,2004,24(1):107-113.
相似文献/References:
[1]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Medical Information,2019,32(12):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[2]厉 锋,鲍 乐,丁轶人,等.安罗替尼治疗晚期肝癌患者的效果[J].医学信息,2020,33(18):138.[doi:10.3969/j.issn.1006-1959.2020.18.045]
LI Feng,BAO Le,DING Yi-ren,et al.Anlotinib in the Treatment of Patients with Advanced Liver Cancer[J].Medical Information,2020,33(12):138.[doi:10.3969/j.issn.1006-1959.2020.18.045]
[3]王鹏飞,李崇慧.加味沙参麦冬汤联合安罗替尼治疗晚期非小细胞肺癌的临床观察[J].医学信息,2021,34(02):167.[doi:10.3969/j.issn.1006-1959.2021.02.047]
WANG Peng-fei,LI Chong-hui.Clinical Observation of Modified Shashen Maidong Decoction Combined with Anlotinib in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2021,34(12):167.[doi:10.3969/j.issn.1006-1959.2021.02.047]
[4]阳 芳,黄 斌,覃超群,等.血清KL-6在安罗替尼治疗的非小细胞肺癌中的表达及临床意义[J].医学信息,2023,36(01):90.[doi:10.3969/j.issn.1006-1959.2023.01.017]
YANG Fang,HUANG Bin,QIN Chao-qun,et al.The Expression and Clinical Significance of Serum KL-6 in Non-small Cell Lung Cancer Treated with Anlotinib[J].Medical Information,2023,36(12):90.[doi:10.3969/j.issn.1006-1959.2023.01.017]